Lindsay N Alfano

List of Publications by Year
in descending order

38 papers	3,505 citations	471477 17 h-index	361001 35 g-index
38 all docs	38 docs citations	38 times ranked	4548 citing authors

#	Article	IF	Citations
1	Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1713-1722.	27.0	1,642
2	Longitudinal effect of eteplirsen versus historical control on ambulation in <scp>D</scp>uchenne muscular dystrophy. Annals of Neurology, 2016, 79, 257-271.	5.3	428
3	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
4	Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. JAMA Neurology, 2020, 77, 1122.	9.0	226
5	Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurology, 2021, 78, 834.	9.0	135
6	AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Diseases, 2019, 6, 307-317.	2.6	124
7	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy, 2017, 25, 870-879.	8.2	84
8	Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. Pediatric Clinics of North America, 2015, 62, 723-742.	1.8	71
9	Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Medicine (United States), 2019, 98, e15858.	1.0	61
10	Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. Human Gene Therapy, 2019, 30, 794-801.	2.7	34
11	Twiceâ€weekly glucocorticosteroids in infants and young boys with Duchenne muscular dystrophy. Muscle and Nerve, 2019, 59, 650-657.	2.2	32
12	Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up. Muscle and Nerve, 2016, 54, 681-689.	2.2	29
13	Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Journal of Neuromuscular Diseases, 2021, 8, 469-479.	2.6	22
14	Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. World Journal of Pediatrics, 2019, 15, 219-225.	1.8	21
15	Assessment of disease progression in dysferlinopathy. Neurology, 2019, 92, .	1.1	20
16	Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23.	2.7	19
17	Development of the sporadic inclusion body myositis physical functioning assessment. Muscle and Nerve, 2016, 54, 653-657.	2.2	17
18	Assessing Dysferlinopathy Patients Over Three Years With a New Motor Scale. Annals of Neurology, 2021, 89, 967-978.	5.3	17

#	Article	IF	Citations
19	Correlation of knee strength to functional outcomes in becker muscular dystrophy. Muscle and Nerve, 2013, 47, 550-554.	2.2	16
20	The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscular Disorders, 2017, 27, 452-457.	0.6	16
21	Reliability and validity of activeâ€seated: An outcome in dystrophinopathy. Muscle and Nerve, 2015, 52, 356-362.	2.2	15
22	Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests. Pediatric Neurology, 2020, 113, 15-20.	2.1	14
23	Modeling functional decline over time in sporadic inclusion body myositis. Muscle and Nerve, 2017, 55, 526-531.	2.2	12
24	Motor Function Test Reliability During the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study. Journal of Neuromuscular Diseases, 2018, 5, 509-521.	2.6	12
25	Psychometric validation of a patient-reported measure of physical functioning in sporadic inclusion body myositis. Muscle and Nerve, 2016, 54, 658-665.	2.2	11
26	ACTIVE (Ability Captured Through Interactive Video Evaluation) workspace volume video game to quantify meaningful change in spinal muscular atrophy. Developmental Medicine and Child Neurology, 2020, 62, 303-309.	2.1	10
27	Emerging therapeutic options for sporadic inclusion body myositis. Therapeutics and Clinical Risk Management, 2015, 11, 1459.	2.0	9
28	Use of the Childrenâ€™s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) in X-Linked Myotubular Myopathy: Content Validity and Psychometric Performance. Journal of Neuromuscular Diseases, 2021, 8, 63-77.	2.6	9
29	Remote Delivery of Motor Function Assessment and Training for Clinical Trials in Neuromuscular Disease: A Response to the COVID-19 Global Pandemic. Frontiers in Genetics, 2021, 12, 735538.	2.3	9
30	Measuring change in inclusion body myositis: clinical assessments versus imaging. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	6
31	Validity and Reliability of the Neuromuscular Gross Motor Outcome. Pediatric Neurology, 2021, 122, 21-26.	2.1	5
32	Assessing the Relationship of Patient Reported Outcome Measures With Functional Status in Dysferlinopathy: A Rasch Analysis Approach. Frontiers in Neurology, 2022, 13, 828525.	2.4	4
33	Development of Duchenne Video Assessment scorecards to evaluate ease of movement among those with Duchenne muscular dystrophy. PLoS ONE, 2022, 17, e0266845.	2.5	4
34	Comparison of strength testing modalities in dysferlinopathy. Muscle and Nerve, 2022, 66, 159-166.	2.2	3
35	Functional outcome measures in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2022, 32, 460-467.	0.6	2
36	Prediction of Clinical Outcomes of Spinal Muscular Atrophy Using Motion Tracking Data and Elastic Net Regression. , 2018, , .		1

#	Article	IF	Citations
37	Random forest: random results or meaningful insights for patients with facioscapulohumeral muscular dystrophy?. Brain, 2021, , .	7.6	0
38	Measuring change in inclusion body myositis: clinical assessments versus imaging.. Clinical and Experimental Rheumatology, 2022, 40, 404-413.	0.8	0